Late-Onset Ataxia Linked to Repeat Expansion in FGF14 Gene
By LabMedica International staff writers Posted on 20 Dec 2022 |

There are many causes of cerebellar ataxia including, among others, gluten ataxia, autoimmunity to Purkinje cells or other neural cells in the cerebellum, CNS vasculitis, multiple sclerosis, infection, bleeding, infarction, tumors, direct injury, toxins, genetic disorders and neurodegenerative diseases (such as progressive supranuclear palsy and multiple system atrophy).
Late-onset cerebellar ataxias (LOCAs) are a heterogeneous group of neurodegenerative disorders manifesting as a progressive cerebellar syndrome that develops after 30 years of age. The prevalence of LOCA is approximately 1 to 3 per 100,000 population, and molecular testing yields negative results in almost 75% of patients with LOCA. This is explained in part by the limitations of standard next-generation sequencing analysis for the identification of certain sequence variations, such as tandem repeat expansions.
A large team of scientists at McGill University (Montreal, QC, Canada), and the University of Miami's Miller School of Medicine (Miami, FL, USA) and other colleagues sequenced the genomes of six persons with autosomal dominant LOCA who were members of three French Canadian families and identified a candidate pathogenic repeat expansion. They then tested for association between the repeat expansion and disease in two independent case–control series: one French Canadian (66 patients and 209 controls) and the other German (228 patients and 199 controls). They also genotyped the repeat in 20 Australian and 31 Indian index patients. They assayed gene and protein expression in two postmortem cerebellum specimens and two induced pluripotent stem-cell (iPSC)–derived motor-neuron cell lines.
The FGF14 repeat locus was amplified by long-range polymerase chain reaction (PCR). The number of repeat units was estimated by means of agarose-gel electrophoresis. The motif of the repeat locus in patients and controls that had large amplification products on long-range PCR was analyzed by targeted long-read nanopore sequencing. They tested for association between LOCA and FGF14 GAA expansions of 250 or more repeats ([GAA]≥250), as measured by agarose-gel electrophoresis of PCR-amplification products. Postmortem cerebellar tissue was obtained from two patients of Spanish origin who carried an FGF14 GAA repeat expansion that had been uncovered after screening of postmortem brain specimens from 15 patients of European descent with unsolved LOCA and seven controls of European descent without ataxia.
The investigators reported that in the six French Canadian patients, they identified a GAA repeat expansion deep in the first intron of FGF14, which encodes fibroblast growth factor 14. Co-segregation of the repeat expansion with disease in the families supported a pathogenic threshold of at least 250 GAA repeats. They detected the repeat expansion in late-onset cerebellar ataxia patients from other populations, albeit in a smaller proportion of cases. They saw the FGF14 repeat expansion in 18% of the German cases and 15% of the Australian cases, but just 10% of late-onset cerebellar ataxia cases from India. In total, they identified 128 patients with LOCA who carried an FGF14 (GAA)≥250 expansion. Postmortem cerebellum specimens and iPSC-derived motor neurons from patients showed reduced expression of FGF14 RNA and protein.
The authors concluded that they had identified a dominant GAA repeat expansion in the first intron of FGF14 in persons with unsolved LOCA. The findings also show how late-onset disorders can be associated with individual alleles of strong genetic effect. The study underscores the importance of identifying noncoding repeat expansions, because they probably account for some of the missing heritability in unsolved neurodegenerative disorders. The study was published on December 14, 2022 in the New England Journal of Medicine.
Related Links:
McGill University
University of Miami's Miller School of Medicine
Latest Molecular Diagnostics News
- Novel Autoantibody Against DAGLA Discovered in Cerebellitis
- Blood Test Could Identify Patients at Risk for Severe Scleroderma
- Gene-Based Blood Test Accurately Predicts Tumor Recurrence of Advanced Skin Cancer
- Rapid Blood Test Identifies Pre-Symptomatic Patients with Parkinson’s Disease
- Blood Test for Early Alzheimer's Detection Achieves Over 90% Accuracy
- RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms
- First Of Its Kind Test Uses microRNAs to Predict Toxicity from Cancer Therapy
- Novel Cell-Based Assay Provides Sensitive and Specific Autoantibody Detection in Demyelination
- Novel Point-of-Care Technology Delivers Accurate HIV Results in Minutes
- Blood Test Rules Out Future Dementia Risk
- D-Dimer Testing Can Identify Patients at Higher Risk of Pulmonary Embolism
- New Biomarkers to Improve Early Detection and Monitoring of Kidney Injury
- Chemiluminescence Immunoassays Support Diagnosis of Alzheimer’s Disease
- Blood Test Identifies Multiple Biomarkers for Rapid Diagnosis of Spinal Cord Injury
- Highly Accurate Blood Test Diagnoses Alzheimer’s and Measures Dementia Progression
- Simple DNA PCR-Based Lab Test to Enable Personalized Treatment of Bacterial Vaginosis
Channels
Clinical Chemistry
view channel
Low-Cost Portable Screening Test to Transform Kidney Disease Detection
Millions of individuals suffer from kidney disease, which often remains undiagnosed until it has reached a critical stage. This silent epidemic not only diminishes the quality of life for those affected... Read more
New Method Uses Pulsed Infrared Light to Find Cancer's 'Fingerprints' In Blood Plasma
Cancer diagnoses have traditionally relied on invasive or time-consuming procedures like tissue biopsies. Now, new research published in ACS Central Science introduces a method that utilizes pulsed infrared... Read moreHematology
view channel
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
In the United States, approximately 15% of pregnant individuals are RhD-negative. However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary.... Read moreImmunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read moreMicrobiology
view channel
Handheld Device Delivers Low-Cost TB Results in Less Than One Hour
Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more
New AI-Based Method Improves Diagnosis of Drug-Resistant Infections
Drug-resistant infections, particularly those caused by deadly bacteria like tuberculosis and staphylococcus, are rapidly emerging as a global health emergency. These infections are more difficult to treat,... Read more
Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read morePathology
view channel
Novel UV and Machine Learning-Aided Method Detects Microbial Contamination in Cell Cultures
Cell therapy holds great potential in treating diseases such as cancers, inflammatory conditions, and chronic degenerative disorders by manipulating or replacing cells to restore function or combat disease.... Read more
New Error-Corrected Method to Help Detect Cancer from Blood Samples Alone
"Liquid biopsy" technology, which relies on blood tests for early cancer detection and monitoring cancer burden in patients, has the potential to transform cancer care. However, detecting the mutational... Read more
"Metal Detector" Algorithm Hunts Down Vulnerable Tumors
Scientists have developed an algorithm capable of functioning as a "metal detector" to identify vulnerable tumors, marking a significant advancement in personalized cancer treatment. This breakthrough... Read more
Novel Technique Uses ‘Sugar’ Signatures to Identify and Classify Pancreatic Cancer Cell Subtypes
Pancreatic cancer is often asymptomatic in its early stages, making it difficult to detect until it has progressed. Consequently, only 15% of pancreatic cancers are diagnosed early enough to allow for... Read moreTechnology
view channel
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more
Innovative, Label-Free Ratiometric Fluorosensor Enables More Sensitive Viral RNA Detection
Viruses present a major global health risk, as demonstrated by recent pandemics, making early detection and identification essential for preventing new outbreaks. While traditional detection methods are... Read moreIndustry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more